Studies from Public Assistance - Paris Hospitals (AP-HP) Update Current Data on Cytomegalovirus (Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the ...)

MLA

“Studies from Public Assistance - Paris Hospitals (AP-HP) Update Current Data on Cytomegalovirus (Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from The ...).” Hematology Week, 4 Jan. 2021, p. 1639. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.647291078&authtype=sso&custid=ns315887.

APA

Studies from Public Assistance - Paris Hospitals (AP-HP) Update Current Data on Cytomegalovirus (Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the ...). (2021, January 4). Hematology Week, 1639.

Chicago

Hematology Week. 2021. “Studies from Public Assistance - Paris Hospitals (AP-HP) Update Current Data on Cytomegalovirus (Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from The ...),” January 4. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.647291078&authtype=sso&custid=ns315887.